Peroxisome proliferator-activated receptor-γ receptor ligand partially prevents the development of endometrial explants in baboons: A prospective, randomized, placebo-controlled study

Endocrinology

Volumn 151, Issue 4, 2010, Pages 1846-1852

  Lebovic, Dan I ^a   Mwenda, Jason M ^b   Chai, Daniel C ^b   Santi, Alessandro ^c   Xu, Xiao ^d   D'Hooghe, Thomas ^b,e  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b INSTITUTE OF PRIMATE RESEARCH   (Kenya)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIUM; EXPLANT; FEMALE; LAPAROSCOPY; MENSTRUAL CYCLE; NONHUMAN; PELVIS; PRIORITY JOURNAL;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; PAPIO ANUBIS; PPAR GAMMA; PROSPECTIVE STUDIES; RANDOM ALLOCATION; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES;

EID: 77950240540     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-1076     Document Type: Article

References (48)

1. Agic A, Xu H, Finas D, Banz C, Diedrich K, Hornung D 2006 Is endometriosis associated with systemic subclinical inflammation? Gynecol Obstet Invest 62:139-147
2. Lebovic DI, Mueller MD, Taylor RN 2001 Immunobiology of endometriosis. Fertil Steril 75:1-10
3. Barrier BF, Bates GW, Leland MM, Leach DA, Robinson RD, Propst AM 2004 Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons. Fertil Steril 81(Suppl 1):775-779
4. D'Hooghe TM, Nugent NP, Cuneo S, Chai DC, Deer F, Debrock S, Kyama CM, Mihalyi A, Mwenda JM 2006 Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Biol Reprod 74:131-136
5. Falconer H, Mwenda JM, Chai DC, Wagner C, Song XY, Mihalyi A, Simsa P, Kyama C, Cornillie FJ, Bergqvist A, Fried G, D'Hooghe TM 2006 Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. Hum Reprod 21:1856-1862
6. Brown JD, Plutzky J 2007 Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115:518-533
7. Willson TM, Brown PJ, Sternbach DD, Henke BR 2000 The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550
8. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK 1998 The peroxisome proliferator-activated receptor-γis a negative regulator of macrophage activation. Nature 391:79-82
9. Jiang C, Ting AT, Seed B 1998 PPAR-γagonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
10. Peeters LL, Vigne JL, Tee MK, Zhao D, Waite LL, Taylor RN 2005 PPAR γ represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis 8:373-379
11. Wu Y, Guo SW 2009 Peroxisome proliferator-activated receptor-γ and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. Fertil Steril 91:2142-2147
12. Mu YM, Yanase T, Nishi Y, Takayanagi R, Goto K, Nawata H 2001 Combined treatment with specific ligands for PPARγ:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells. Mol Cell Endocrinol 181:239-248
13. Yanase T, Mu YM, Nishi Y, Goto K, Nomura M, Okabe T, Takayanagi R, Nawata H 2001 Regulation of aromatase by nuclear receptors. J Steroid Biochem Mol Biol 79:187-192
14. Fan W, Yanase T, Morinaga H, Mu YM, Nomura M, Okabe T, Goto K, Harada N, Nawata H 2005 Activation of peroxisome proliferator-activated receptor-γ and retinoid X receptor inhibits aromatase transcription via nuclear factor-κB. Endocrinology 146:85-92
15. Ohama Y, Harada T, Iwabe T, Taniguchi F, Takenaka Y, Terakawa N 2008 Peroxisome proliferator-activated receptor-γ ligand reduced tumor necrosis factor-α-induced interleukin-8 production and growth in endometriotic stromal cells. Fertil Steril 89:311-317
16. McKinnon B, Bersinger NA, Huber AW, Kuhn A, Mueller MD 2009 PPAR-γexpression in peritoneal endometriotic lesions correlates with pain experienced by patients. Fertil Steril 93:293-296
17. Lebovic DI, Kir M, Casey CL 2004 Peroxisome proliferator-activated receptor-γinduces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 82(Suppl 3):1008-1013
18. Aytan H, Caliskan AC, Demirturk F, Aytan P, Koseoglu DR 2007 Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reduces the size of experimental endometriosis in the rat model. Aust NZ J Obstet Gynaecol 47:321-325
19. Demirturk F, Aytan H, Caliskan AC, Aytan P, Koseoglu DR 2006 Effect of peroxisome proliferator-activated receptor-γ agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investig 13:58-62
20. Demirturk F, Aytan H, Caliskan A, Aytan P, Yener T, Koseoglu D, Yenisehirli A 2006 The effect of rosiglitazone in the prevention of intra-abdominal adhesion formation in a rat uterine horn model. Hum Reprod 21:3008-3013
21. Lebovic DI, Mwenda JM, Chai DC, Mueller MD, Santi A, Fisseha S, D'Hooghe T 2007 PPAR-γ receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 88:1108-1119
22. D'Hooghe TM, Bambra CS, Raeymaekers BM, De Jonge I, Hill JA, Koninckx PR 1995 The effects of immunosuppression on development and progression of endometriosis in baboons (Papio anubis). Fertil Steril 64:172-178
23. Falconer H, Mwenda JM, Chai DC, Wagner C, Song XY, Mihalyi A, Simsa P, Kyama C, Cornillie FJ, Bergqvist A, Fried G, D'Hooghe TM 2006 Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. Hum Reprod 21:1856-1862
24. D'Hooghe TM, Bambra CS, Raeymaekers BM, De Jonge I, Lauweryns JM, Koninckx PR 1995 Intrapelvic injection of menstrual endometrium causes endometriosis in baboons (Papio cynocephalus and Papio anubis). Am J Obstet Gynecol 173:125-134
25. Stevens VC 1997 Some reproductive studies in the baboon. Hum Reprod Update 3:533-540
26. Kriewaldt FH, Hendrickx AG 1968 Reproductive parameters of the baboon. Lab Anim Care 18:361-370
27. Kyama CM, Overbergh L, Debrock S, Valckx D, Vander Perre S, Meuleman C, Mihalyi A, Mwenda JM, Mathieu C, D'Hooghe TM 2006 Increased peritoneal and endometrial gene expression of biologically relevant cytokines and growth factors during the menstrual phase in women with endometriosis. Fertil Steril 85:1667-1675
28. D'Hooghe TM, Bambra CS, Xiao L, Peixe K, Hill JA 2001 Effect of menstruation and intrapelvic injection of endometrium on inflammatory parameters of peritoneal fluid in the baboon (Papio anubis and Papio cynocephalus). Am J Obstet Gynecol 184:917-925
29. Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J 2008 The peroxisome proliferator-activated receptor-γ agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-α-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol 52:869-881
30. Kavoussi SK, Witz CA, Binkley PA, Nair AS, Lebovic DI 2009 Peroxisome-proliferator activator receptor-γ activation decreases attachment of endometrial cells to peritoneal mesothelial cells in an in vitro model of the early endometriotic lesion. Mol Hum Reprod 15:687-692
31. Burney RO, Lathi RB 2009 Menstrual bleeding from an endometriotic lesion. Fertil Steril 91:1926-1927
32. Lebovitz HE, Kreider M, Freed MI 2002 Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25: 815-821
33. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet 366: 1279-1289
34. Zinn A, Felson S, Fisher E, Schwartzbard A 2008 Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol 31:397-403
35. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE 2007 Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180-1188
36. Deeg MA, Tan MH 2008 Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res 2008:520465
37. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
38. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G 2008 Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care 31:845-851
39. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H 2004 PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846-855
40. Wan Y, Chong LW, Evans RM 2007 PPAR-γ regulates osteoclastogenesis in mice. Nat Med 13:1496-1503
41. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B 2006 Netoglitazone is a PPAR-γ ligand with selective effects on bone and fat. Bone 38:74-84
42. Motani A, Wang Z, Weiszmann J, McGee LR, Lee G, Liu Q, Staunton J, Fang Z, Fuentes H, Lindstrom M, Liu J, Biermann DH, Jaen J, Walker NP, Learned RM, Chen JL, Li Y 2009 INT131: a selective modulator of PPAR γ. J Mol Biol 386:1301-1311
43. Moravek MB, Ward EA, Lebovic DI 2009 Thiazolidinediones as therapy for endometriosis: a case series. Gynecol Obstet Invest 68:167-170
44. Ota H, Goto T, Yoshioka T, Ohyama N 2008 Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril 90:709-713
45. Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, Chang RJ, Henry RR 2009 Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 94:469-476
46. Coffler MS, Patel K, Dahan MH, Yoo RY, Malcom PJ, Chang RJ 2003 Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. J Clin Endocrinol Metab 88: 5624-5631
47. Sheng X, Zhang Y, Gong Z, Huang C, Zang YQ 2008 Improved insulin resistance and lipid metabolism by cinnamon extract through activation of peroxisome proliferator-activated receptors. PPAR Res 2008:581348
48. Christensen KB, Petersen RK, Petersen S, Kristiansen K, Christensen LP 2009 Activation of PPARγ by metabolites from the flowers of purple coneflower (Echinacea purpurea). J Nat Prod 72:933-937